MS Speaks
Multiple Sclerosis => TREATMENTS => Topic started by: agate on March 09, 2017, 06:58:58 am
-
From PubMed, March 9, 2017:
Can J Neurol Sci. 2017 Mar 8:1-9.
Patient-Reported Benefits of Extracranial Venous Therapy: British Columbia CCSVI Registry
Sadovnick AD1, Yee IM1, Attwell-Pope K2, Keyes G3, Kipp L4, Traboulsee AL4.
Author information:
1
1Department of Medical Genetics,University of British Columbia,Vancouver,British Columbia,Canada.
2
2Vancouver Island Health Authority,Victoria,British Columbia,Canada.
3
3Wellington Medical Clinic,Nanaimo,British Columbia,Canada.
4
4Department of Medicine (Neurology),University of British Columbia,Vancouver,British Columbia,Canada.
Objective
Chronic cerebrospinal venous insufficiency (CCSVI) has been hypothesized to be a risk factor for multiple sclerosis (MS). Venoplasty has been proposed as a treatment for CCSVI. The aim of our study was to gain a better understanding of the "real-world" safety and longitudinal effectiveness of venoplasty
Methods:
British Columbia residents who self-reported having had venoplasty and consented to participate in the study were interviewed and followed for up to 24 months post-therapy using standardized structured questionnaires Results: Participants reported procedure-related complications (11.5%) and complications within the first month after the procedure (17.3%). Initially, more than 40% of participants perceived that the venoplasty had had positive effects on their health conditions, such as fatigue, numbness, balance, concentration/memory and mobility. However, this improvement was not maintained over time
Conclusions:
Follow-up patient-reported outcomes indicated that the initial perception of the positive impact of venoplasty on the health conditions of MS patients was not sustained over time. In addition, venoplasty was not without associated morbidity.
The abstract can be seen at https://www.ncbi.nlm.nih.gov/pubmed/28270250 (https://www.ncbi.nlm.nih.gov/pubmed/28270250).